ATR and cancer: Secondly, AZD6738 is another potent, selective, oral ATR inhibitor that demonstrated radiosensitization in a panel of human cancer cell lines independent of the p53 or BRCA2 status and is currently tested in phase 1 clinical trials as monotherapy or in combination with radiotherapy, chemotherapy or Olaparib [19, 21, 85].